What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical trial HIMALAYA demonstrated a statistically significant improvement in median overall survival (OS) for durvalumab with tremelimumab compared to sorafenib (16.43 months vs. 13.77 months). Although the progression-free survival (PFS) data was not statistically significant, the clinical experts noted that this pattern is plausible for immunotherapy treatments. The evidence suggests a clear clinical advantage over the standard of care.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for durvalumab with tremelimumab are within the acceptable range for NHS resources, with an ICER below £30,000 per QALY gained. This suggests that the treatment is marginally cost-effective and defensible, especially considering the potential uncaptured benefits.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that durvalumab with tremelimumab has a positive impact on HRQoL, as noted by patient expert testimonies regarding the distressing symptoms of untreated HCC. However, specific validated tools measuring HRQoL improvements were not detailed in the document, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of durvalumab with tremelimumab is considered very good, with mostly mild or moderate adverse events reported. The committee noted that the treatment’s side-effect profile differs from existing options, which may provide a better tolerability for some patients.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was compared against appropriate standard-of-care alternatives, including sorafenib and atezolizumab with bevacizumab. The committee acknowledged that while there are some limitations in the direct comparisons, the use of indirect comparisons through network meta-analysis was justified.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in HIMALAYA is considered moderately representative of the intended patient population, although there were some concerns about the generalizability due to the absence of UK sites. The committee concluded that the baseline characteristics were consistent with NHS patients.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Durvalumab with tremelimumab can be integrated into existing treatment pathways with minor adjustments. The committee noted that it fits well within the current treatment landscape for HCC, requiring no significant changes to infrastructure.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of durvalumab with tremelimumab is manageable, with the potential for net savings due to its cost-effectiveness. The committee noted that the treatment is likely to be affordable at scale, especially with the commercial arrangement in place.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a robust Phase 3 trial (HIMALAYA) with low bias risk. However, there are some methodological concerns regarding the network meta-analysis and the potential for bias in investigator-assessed outcomes, which slightly lowers the rating.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term benefits and the robustness of the cost-effectiveness model, the committee noted that these are manageable and do not significantly undermine the overall positive assessment of the treatment.
